

Gemini Stock Analysis Report

Okay, I will analyze the provided report for DIVISLAB.NS with the goal of identifying a potential positional trade setup.

Step 1: Audit the Data

- **Data Present:** Daily price chart, EMA crossover analysis, Bollinger Bands, Supertrend analysis, MACD, Relative Strength analysis, Volatility Squeeze, RSI-Volume divergence analysis, Fundamental Analysis.
- **Data Missing:** Weekly chart, Institutional ownership data, Analyst ratings, News flow or recent developments surrounding the company.
- **Confidence Level:** Medium. The report offers several technical indicators and some fundamental data, but the absence of weekly chart and other information limits the depth of the analysis.

Step 2: Analyze the Setup

Based on the provided report, here's a breakdown of the setup:

- **Price Structure:** The 3-year daily price chart shows a generally upward trend, but with recent volatility. The price is currently around INR 6478.50.
- **Trend Direction:**
 - **Long-term:** The 3-year chart suggests an overall uptrend, although growth has been slow.
 - **Intermediate-term:** The stock is displaying short-term downtrend EMA crossover.

Momentum:

- **Relative Strength (RS):** RS rating shows a weakening leader. Emerging RS is negative, indicating no acceleration. This implies weakness in its peer group.
- **MACD:** Signal shows a bullish crossover, but with weakening momentum.
- **Supertrend:** Indicates a "DOWNTREND (Sell)" signal.

Key Indicators & Confluence:

- **EMA Crossover:** Indicates short-term downtrend.
- **Bollinger Bands:** Price in the upper half of the bands; however, the volatility squeeze suggests a potential for a breakout, but the direction is uncertain.
- **RSI-Volume Divergence:** **Bullish** divergence present, suggesting potential for price to rise.
- **Fundamentals:** Positive trends in revenue, but mixed picture on net income and return metrics.
- **Supertrend and EMA Crossover** indicate a downtrend but MACD indicates a possible buy, which is a mixed trend signal.

Step 3: Formulate the Recommendation

Based on the analysis, I recommend **against** entering a long position in DIVISLAB.NS at this time.

Reason for Invalid Setup: The technical indicators present a mixed picture, characterized by a short-term downtrend signals from the EMA crossovers and Supertrend. The weakening relative strength is also concerning. The bullish divergence provides a counterargument, but is not convincing enough given the other bearish signals. The conflicting signals of EMA crossover and Supertrend and MACD indicate more volatility.

Conditional Plan:

- **Condition to Buy:** Wait for confirmation of trend reversal. Specifically, I would want to see the price

Gemini Stock Analysis Report

close above the Supertrend value (6618.14) **and** the 20-day EMA, indicating a shift back to an uptrend.

- **Entry Price:** INR 6620 (After closing above 6618.14)
- **Stop Loss:** INR 6300 (Just below the recent support level)
- **Take Profit:** INR 7200 (Approximately 5% to 15% upside potential)

I've taken a conservative approach given the contradictory signals and the focus on identifying high-probability setups. I recommend monitoring DIVISLAB.NS for the specified conditions before considering a long position.

News & Analyst Targets

Okay, I will act as a stock research analyst and gather the latest information on DIVISLAB for you. Here's what I've found based on my search:

Here's a summary of the latest news and information regarding DIVISLAB, gathered this week:

1. Latest News for DIVISLAB This Week:

- **Increased Open Interest:** On December 19, 2025, Divis Laboratories recorded a surge in open interest in its derivatives segment, indicating heightened activity and evolving market positioning.
- **Outperformance:** DIVISLAB outperformed its sector with a one-day return of 2.36% compared to the Pharmaceuticals & Biotechnology sector's 0.80% and the Sensex's 0.61%.
- **Technical Indicators:** The stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signaling sustained upward momentum.
- **Increased Investor Engagement:** Delivery volumes reached 2.76 lakh shares on December 18, a 153.89% rise compared to the five-day average, suggesting stronger investor conviction.
- **Volatility:** Divis Laboratories has faced notable volatility and opened with a loss, underperforming its sector.
- **Technical Downtrend:** The stock has seen a consecutive decline over two days and is trading below key moving averages, indicating a bearish trend.
- **Analyst Ratings:** In the current month, DIVISLAB has received 4 Buy Ratings, 7 Hold Ratings, and 3 Sell Ratings.
- **Buy Signal:** Bulls are in the driving seat as a 50-day moving crossover appeared.
- **Revenue Growth:** Company's annual revenue growth of 18.67% outperformed its 3-year CAGR of 2.27%.

2. Brokerage Upgrades and Downgrades for DIVISLAB:

- **Geojit Downgrade (September 10, 2025):** Geojit Investments downgraded the stock to "Reduce" with a target price of Rs 5,400, citing persistent pricing pressure in generics and higher cost escalation.
- **BofA Upgrade (April 4, 2024):** BofA Securities upgraded Divi's Laboratories to "Buy" from "Underperform" with a revised target price of Rs 4,025.
- **Jefferies Upgrade:** Jefferies analyst Dhawal Khut upgraded Divi's Laboratories Ltd (DIVI:IN) from Hold to Buy with a price target of INR7,150.00 (from INR6,750.00).
- **HSBC Upgrade (July 8, 2025):** HSBC upgraded Divi's Laboratories Ltd from "Reduce" to "Buy," raising the price target to INR7,900.00 from INR5,020.00, citing growth potential in the custom synthesis segment.

3. Other News Impacting DIVISLAB:

- **Entresto Patent Ruling (December 6, 2024):** Shares of Divi's Laboratories fell after the US Appellate Court rejected Novartis's attempt to block generic manufacturing of Entresto. While the exact revenue from Entresto-related supplies is undisclosed, it contributes a meaningful share to the overall business.
- **Tariffs (July 2025):** Concerns about potential tariffs may cause investors to avoid the stock for a short period.

Gemini Stock Analysis Report

- **FDA Inspection:** Regulation 30 Disclosure - US-FDA Inspection Of Company'S Unit-I Manufacturing Facili.

4. Analyst Targets for DIVISLAB:

Here is a table summarizing the latest analyst targets for DIVISLAB:

Analyst/Brokerage	Target Price (INR)	Rating
Average (Multiple Sources)	6,785.10 - 6,866.67	HOLD/Moderate Buy
High	9,140.00 - 9,597	N/A
Low	4,486.00 - 4,930 - 5,400	N/A
HSBC	7,900.00	Buy
Jefferies	7,150.00 - 7,850	Buy
JPMorgan	7,800.00	Overweight
Geojit	5,400.00	Reduce
HSBC analyst Damayanti Kerai	7,400.00	Buy

Disclaimer: Analyst targets and ratings can change frequently and may not be entirely up-to-date. This information is for informational purposes only and should not be considered financial advice. Please consult with a qualified financial advisor before making any investment decisions.


Stock Detailed Analysis Report

DIVISLAB.NS

Current Price: ₹6478.50

Generated: 2025-12-20 20:44

DIVISLAB.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	19.61%	1.95%
Net Income	No	Yes	36.94%	-9.55%
ROE	No	Yes	24.15%	-16.61%
EPS	No	Yes	36.93%	-9.55%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	-5.49%	3.51%
Net Income	Yes	-17.67%	7.20%
ROE	Yes	18.95%	18.95%
EPS	Yes	15.62%	17.07%

DIVISLAB.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Weakening Leader
RS Score:	50.2/100
:	

== RS RATIOS ==:

1M RS:	1.000 [Neutral]
3M RS:	1.037 [Leader]
6M RS:	0.926 [Neutral]
1Y RS:	1.079 [Leader]
:	


== TURNAROUND ANALYSIS ==:

Turnaround Status:	Not Detected
:	


SIGNAL CRITERIA::

✗ Emerging RS:	Not accelerating
✓ Medium-term Lagging:	6M=0.926 (≤ 1.0)
✓ Performance Improving:	3M (+4.5%) > 6M (-1.7%)


Relative Strength Analysis: DIVISLAB.NS vs ^CNXPHARMA
Classification: Weakening Leader
Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)




RS Composite Score Timeline



DIVISLAB.NS - EMA Crossover Summary

EMA 20:	6409.48
EMA 50:	6415.47
EMA 200:	6216.53
Trend Status:	Short-term Downtrend
Golden Cross Date:	2024-04-25 00:00:00
Golden Cross Price:	3843.80

DIVISLAB.NS EMA Crossover Analysis



DIVISLAB.NS - Bollinger Bands Summary

Current Price:	6478.50
Upper Band:	6546.58
Middle Band (SMA 20):	6404.70
Lower Band:	6262.82
%B:	0.7601
Band Width:	0.0443
Status:	Upper Half
Signal:	None
Recent Signal 1:	Buy Signal at 2025-09-30 00:00:00

DIVISLAB.NS Bollinger Bands (20, 2) Analysis




DIVISLAB.NS - Supertrend Summary

Status: DOWNTREND (Sell)

Supertrend Value: 6618.14

Signal Identified On: 2025-11-18

Supertrend Analysis for DIVISLAB.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




DIVISLAB.NS - MACD Summary

MACD Line:	-26.77
Signal Line:	-30.74
Histogram:	3.97
Trend:	Bullish
Momentum:	Weakening
Signal:	Bullish Crossover (Buy)

DIVISLAB.NS Price






DIVISLAB.NS MACD (12, 26, 9)



DIVISLAB.NS - Volatility Squeeze Summary

BB Width:	0.0443
ATR:	127.7857
Total Signals:	23
Signal 1:	BB Squeeze at 2025-12-15 00:00:00 (Price: 6347.50)
Signal 2:	BB Squeeze at 2025-12-16 00:00:00 (Price: 6335.50)
Signal 3:	BB Squeeze at 2025-12-17 00:00:00 (Price: 6293.00)
Signal 4:	BB Squeeze at 2025-12-18 00:00:00 (Price: 6380.00)
Signal 5:	BB Squeeze at 2025-12-19 00:00:00 (Price: 6478.50)

DIVISLAB.NS - Volatility Squeeze Analysis



DIVISLAB.NS - RSI-Volume Summary

Current RSI:	54.17
Current Volume:	785205
Volume MA 20:	234228
Bullish Divergences:	1
Bearish Divergences:	1
Bullish Div 1:	Date: 2025-12-17 00:00:00, Price: 6293.00
Bearish Div 1:	Date: 2024-07-10 00:00:00, Price: 4636.95

DIVISLAB.NS RSI-Volume Divergence Analysis

